Patents-Review.com
🔗 Permalink
Assignee profile:

AROG PHARMACEUTICALS, INC.

City:

Plano, Texas

Country:

United States

Published Applications:

16

Last publication date:

2024-07-11

Patent Grants:

16

Last grant date:

2025-08-12

Top Inventors for applications by AROG PHARMACEUTICALS, INC.

These are the the leading inventors for applications assigned to AROG PHARMACEUTICALS, INC.:

Recent patent applications by AROG PHARMACEUTICALS, INC.

AROG PHARMACEUTICALS, INC. based in Plano, US has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:

#1 | 2024-07-11 ✅ Patent 12,383,549 granted on 2025-08-12
US20240226088A1
Human necessities

NOVEL COMBINATION THERAPY OF CRENOLANIB AND APOPTOSIS PATHWAY AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

 #2 | 2024-03-28 ✅ Patent 12,295,948 granted on 2025-05-13
US20240100040A1
Human necessities

Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment

 #3 | 2023-04-27 ✅ Patent 11,857,546 granted on 2024-01-02
US20230128591A1
Human necessities

Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment

 #4 | 2022-12-29 ✅ Patent 12,171,757 granted on 2024-12-24
US20220409610A1
Human necessities

Crenolanib for treating FLT3 mutated proliferative disorders

 #5 | 2022-07-14 ✅ Patent 12,662,706 granted on 2026-06-23
US20220218694A1
Human necessities

CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS

 #6 | 2022-05-05 ✅ Patent 11,969,420 granted on 2024-04-30
US20220133710A1
Human necessities

Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders

 #7 | 2022-03-17 ✅ Patent 11,524,006 granted on 2022-12-13
US20220079933A1
Human necessities

Crenolanib for treating TRK kinase associated proliferative disorders

 #8 | 2021-10-21 ✅ Patent 12,404,555 granted on 2025-09-02
US20210324481A1
Chemistry; metallurgy

Crenolanib for Treating FLT3 Mutated Proliferative Disorders Associated Mutations

 #9 | 2021-08-19 ✅ Patent 12,534,764 granted on 2026-01-27
US20210251980A1
Human necessities

CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS ASSOCIATED MUTATIONS

 #10 | 2021-04-08 ✅ Patent 11,642,340 granted on 2023-05-09
US20210100789A1
Human necessities

Method of inhibiting mutant C-KIT

 #11 | 2021-02-25 ✅ Patent 11,471,451 granted on 2022-10-18
US20210052571A1
Human necessities

Uses of crenolanib

 #12 | 2020-12-17 ✅ Patent 11,458,131 granted on 2022-10-04
US20200390756A1
Human necessities

Crenolanib for treating FLT3 mutated proliferative disorders

 #13 | 2020-12-03 ✅ Patent 11,738,017 granted on 2023-08-29
US20200375976A1
Human necessities

Method of inhibiting constitutively active phosphorylated FLT3 kinase

 #14 | 2020-06-18 ✅ Patent 11,602,533 granted on 2023-03-14
US20200188385A1
Human necessities

Crenolanib combination therapy

 #15 | 2019-06-20 ✅ Patent 10,835,525 granted on 2020-11-17
US20190183880A1
Human necessities

Method of inhibiting mutant C-KIT

 #16 | 2018-05-03 ✅ Patent 11,078,541 granted on 2021-08-03
US20180117031A1
Human necessities

Crenolanib for treating FLT3 mutated proliferative disorders associated mutations

Also check out Arog Pharmaceuticals, Inc.'s (Plano, United States) applicant profile with 13 patent applications submitted.

AssigneeID:

348739 ⎘